EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Thrombotic Microangiopathy Associated with Systemic Adeno-Associated Virus Gene Transfer: Review of Reported Cases

Genevieve A Laforet iD

Human Gene Therapy · 2025-02 · 36 (3-4) · 64-76

DOI: 10.1089/hum.2024.156 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Human Gene Therapy, online erschienen am 10.02.2025. Verfasst von Genevieve A Laforet. Beteiligte Einrichtung: BridgeBio Gene Therapy, Palo Alto, California, USA. Hauptthemen laut MEDLINE: Dependovirus, Thrombotic Microangiopathies, Genetic Therapy, Genetic Vectors. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 57 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Complement-mediated thrombotic microangiopathy (TMA) in the form of atypical hemolytic uremic syndrome (aHUS) has emerged as an immune complication of systemic adeno-associated virus (AAV) gene transfer that was unforeseen based on nonclinical studies. Understanding this phenomenon in the clinical setting has been limited by incomplete data and a lack of uniform diagnostic and reporting criteria. While apparently rare based on available information, AAV-associated TMA/aHUS can pose a substantial risk to patients including one published fatality. Reported cases were originally limited to pediatric Duchenne muscular dystrophy patients receiving micro- or mini-dystrophin transgenes via AAV9 but have subsequently been reported in both pediatric and adult patients across a range of disorders, transgenes, promoters, and AAV capsid types. This article provides an introduction to the complement system, TMA and aHUS, and anticomplement therapies, then presents clinical reviews of AAV-associated TMA/aHUS cases that have been reported publicly. Finally, exploration of risk factors and current and future mitigation approaches are discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DependovirusThrombotic MicroangiopathiesGenetic TherapyGenetic VectorsGene Transfer TechniquesAtypical Hemolytic Uremic SyndromeHumansComplement System Proteins

Stichwörter der Autor:innen

adeno-associated virus (AAV)atypical hemolytic uremic syndrome (aHUS)complement activationgene therapy safetythrombotic microangiopathy (TMA)

Substanzen

Complement System Proteins

Autor:innen und Institutionen

  • BridgeBio Gene Therapy, Palo Alto, California, USA.

ORCID-Profile: Genevieve A Laforet

Zitieren

APA

Laforet, G. A. (2025). Thrombotic Microangiopathy Associated with Systemic Adeno-Associated Virus Gene Transfer: Review of Reported Cases. Human Gene Therapy, 36(3-4), 64-76. https://doi.org/10.1089/hum.2024.156

Vancouver

Laforet GA. Thrombotic Microangiopathy Associated with Systemic Adeno-Associated Virus Gene Transfer: Review of Reported Cases. Human Gene Therapy. 2025;36(3-4):64-76. doi:10.1089/hum.2024.156

BibTeX
@article{Laforet2025,
  author = {Laforet, Genevieve A},
  title = {Thrombotic Microangiopathy Associated with Systemic Adeno-Associated Virus Gene Transfer: Review of Reported Cases},
  journal = {Human Gene Therapy},
  year = {2025},
  volume = {36},
  number = {3-4},
  pages = {64--76},
  doi = {10.1089/hum.2024.156}
}
Kostenlos starten →